Complex Regional Pain Syndrome Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Report Overview

Global complex regional pain syndrome market reached US$ YY million in 2023 and is expected to reach US$ YY million by 2031, growing at a CAGR of YY% during the forecast period 2024-2031.

Complex regional pain syndrome (CRPS) is a form of chronic pain that usually affects an arm or a leg. Complex regional pain syndrome (CRPS) typically develops after an injury, surgery, a stroke or a heart attack. The pain is out of proportion to the severity of the initial injury. Treatment is most effective when started early. In such cases, improvement and even remission are possible.

CRPS occurs in two types, with similar signs and symptoms, but different causes. Type 1 also known as reflex sympathetic dystrophy (RSD), occurs after an illness or injury that didn't directly damage the nerves in the affected limb. About 90% of people with CRPS have type 1. Type 2, once referred to as causalgia, this type has symptoms similar to those of type 1. However, type 2 CRPS occurs after a distinct nerve injury. In more than 90% of cases, CRPS results from nerve trauma or injury to the affected limb that damages the thinnest sensory and autonomic nerve fibers. These small fibers transmit pain, itch and temperature sensations. They also control the small blood vessels and the overall health of surrounding cells.

Market Scope

For more details on this report - Request for Sample

Market Dynamics: Drivers

Increasing demand for neurostimulators 

The increasing demand for neurostimulators to better manage the condition is expected to drive the market over the forecast period. The use of non-invasive neurostimulation techniques for the management of complex regional pain syndrome is based on its potential to influence the neuronal plasticity related to the condition. These techniques include cortical and peripheral repetitive transcranial magnetic stimulation, transcranial direct current stimulation (tDCS) and transcutaneous electrical nerve stimulation (TENS).

For instance, on January 14, 2021, Boston Scientific announced the market release of the WaveWriter Alpha portfolio of Spinal Cord Stimulator (SCS) systems. The unified portfolio of four MRI conditional, Bluetooth-enabled rechargeable and non-rechargeable implantable pulse generators (IPGs) provides uncompromised personalization and for the first time in SCS, Fast Acting Sub-perception Therapy (FAST) designed to deliver profound paresthesia-free pain relief in minutes. 

In addition, these systems are supported by the Cognita Solutions suite of digital tools for patients and physicians. The WaveWriter Alpha SCS Systems were approved by the U.S. Food and Drug Administration and are indicated as an aid in the management of chronic intractable pain, Complex Regional Pain Syndrome Types I and II, intractable low back pain and leg pain.

Neurostimulation can help in alleviating chronic pain by interrupting or modulating pain signals before they reach the brain. Some individuals with CRPS may experience improved physical functioning and quality of life with neurostimulation. Neurostimulation may offer an alternative or adjunct to traditional pain medications by reducing the reliance on pharmaceutical interventions. Compared to some surgical interventions, neurostimulation procedures are often reversible and may have fewer associated risks.

For instance, Abbott’s new DRG Invisible Trial System is approved by the U.S. Food and Drug Administration (FDA) for complex chronic pain conditions. The DRG Invisible Trial System to try Abbott's dorsal root ganglion (DRG) stimulation, a clinically proven, non-opioid treatment option for targeted chronic pain management. Focal chronic pain conditions, including complex regional pain syndrome (CRPS), are some of the most prevalent and undertreated forms of chronic pain around the world.

Further, the increasing prevalence of complex regional pain syndrome, rising FDA approvals for better therapeutics, increasing clinical trials to launch more advanced therapies, increasing awareness about the condition and available medications and increasing technological advancements are the factors expected to drive the market over the forecast period.

Restraints

Factors such as complications associated with the high doses of medications, the high cost of the treatment of CRPS, lack of awareness and the availability of alternative treatment options are the factors expected to hamper the market. 

Segment Analysis

The global complex regional pain syndrome market is segmented based on disease type, treatment type, sales channel and region.

The therapies segment accounted for approximately 48.8% of the complex regional pain syndrome market share

The therapies segment including physical therapy, rehabilitation therapy and occupational therapy among others are expected to hold the largest market share over the forecast period. Physical and occupational therapies by gentle, guided exercising of the affected limbs or modifying daily activities might help decrease pain and improve range of motion and strength. The earlier the disease is diagnosed, the more effective exercises might be.

There is an increasing technological advancements in developing different types of therapies like rehabilitation therapies, heat therapies and neurostimulation therapies, which offer better results in patients with complex regional pain syndrome. So, many market players and research hospitals are focussing on developing these advanced therapies with many advancements like virtual reality.

For instance, on December 15, 2021, Jolly Good Inc. in collaboration with Aichi Medical University Hospital's Pain Center will research the efficacy of virtual reality (VR) therapy for chronic pain. In the first phase of this research, Jolly Good and Aichi Medical University plan to study the development of rehabilitation therapy using VR for people with complex regional pain syndrome (CRPS), post-stroke pain and other conditions that cause pain or fear of movement.

Geographical Analysis

North America accounted for approximately 41.7% of the market share 

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and increasing research activities. North America especially the United States is well-known for its strong presence of major players such as pharmaceutical companies and medical device companies. The strong presence of major players are actively performing in clinical trials, which leads to the launch of novel therapeutics and advanced therapies.

For instance, on September 9, 2021, Soin Therapeutics was granted orphan drug status from the FDA for low-dose naltrexone (LDN) to treat complex regional pain syndrome (CRPS). Naltrexone is a medication that is primarily used to manage alcohol or opioid use disorder by reducing cravings or feelings of euphoria associated with substance use disorder. It has also been shown in anecdotal reports to alleviate symptoms stemming from CRPS at very low doses (approximately 1/10th the dose) of currently approved indications. When the dose of the drug is substantially lowered, the pharmacological effects change favorably to treat CRPS.

In addition, increasing research activities are also helps to develop more advanced therapeutics for the better management of the symptoms in the early stages by preventing further complications. As the research activities increase, the therapeutics are developed more precisely by reducing the adverse effects and complications associated with the therapeutics, which results in better patient outcomes.

For instance, on June 28, 2023, JanOne Inc., a biopharmaceutical company that is developing multiple drugs to treat chronic diseases like Peripheral Artery Disease (PAD) and Complex Regional Pain Syndrome (CRPS), filed an international patent application for methods of using low dose naltrexone to treat chronic pain.

Competitive Landscape

The major global players in the complex regional pain syndrome market include Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, Nevro Corp., St. Jude Medical, Saluda Medical Pty Ltd., Almatica Pharma LLC, Johnson & Johnson Consumer Inc., Biotronik SE & Co. KG and GIMER Medical among others. 

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global complex regional pain syndrome market. During the pandemic, the ongoing clinical trials for new medications or therapies targeting CRPS are temporarily halted or postponed due to the redirected focus towards COVID-19. Restrictions on patient visits, reduced access to healthcare facilities and prioritization of resources for COVID-19-related research might have delayed trial timelines. The pandemic also disrupted the supply chain of these treatment drugs and devices globally.

Why Purchase the Report?

• To visualize the global complex regional pain syndrome market segmentation based on disease type, treatment type, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of complex regional pain syndrome market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global complex regional pain syndrome market report would provide approximately 61 tables, 56 figures and 187 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies